Display options
Cite
Owen EJ, Siddle NC, McGarrigle HT, et al. 25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?. Br J Obstet Gynaecol. 1992;99(8):671-5doi: 10.1111/j.1471-0528.1992.tb13853.x.
Owen, E. J., Siddle, N. C., McGarrigle, H. T., & Pugh, M. A. (1992). 25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?. British journal of obstetrics and gynaecology, 99(8), 671-5. https://doi.org/10.1111/j.1471-0528.1992.tb13853.x
Owen, E J, et al. "25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?." British journal of obstetrics and gynaecology vol. 99,8 (1992): 671-5. doi: https://doi.org/10.1111/j.1471-0528.1992.tb13853.x
Owen EJ, Siddle NC, McGarrigle HT, Pugh MA. 25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?. Br J Obstet Gynaecol. 1992 Aug;99(8):671-5. doi: 10.1111/j.1471-0528.1992.tb13853.x. PMID: 1327094.
Copy Download .nbib Format: NLM
Share it on

Br J Obstet Gynaecol. 1992 Aug;99(8):671-5. doi: 10.1111/j.1471-0528.1992.tb13853.x.

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?.

British journal of obstetrics and gynaecology

E J Owen, N C Siddle, H T McGarrigle, M A Pugh

Affiliations

  1. Department of Obstetrics and Gynaecology, University College and Middlesex Hospitals, London, UK.

PMID: 1327094 DOI: 10.1111/j.1471-0528.1992.tb13853.x

Abstract

OBJECTIVE: To assess the oestrogen concentrations and symptom relief obtained with 25 mg oestradiol implants.

DESIGN: Open, observational study.

SUBJECTS: Twelve symptomatic, post-menopausal women seen in a designated menopause clinic.

INTERVENTION: A 25 mg oestradiol pellet was inserted subcutaneously, blood samples were obtained before implantation and at regular intervals (2-4 weeks) until symptoms refused as hypoestrogenaemia developed.

MAIN OUTCOME MEASURES: Change in symptom score following implant treatment. Concentrations of oestrogens and their metabolites before and during low dose subcutaneous oestradiol therapy.

RESULTS: Ten of the 12 women had excellent symptom relief, associated with oestradiol concentrations in the follicular range for between 28 and 35 weeks. The ratio of circulating oestrogen metabolites remained physiological, despite the oestradiol concentrations being substantially higher on treatment.

CONCLUSIONS: We suggest that 25 mg pellets should be used as the initial dose for subcutaneous oestrogen treatment, and a combination of return of symptoms and weeks since insertion used to judge the timing of reimplantation.

Similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources